Revvity, Inc. (NYSE:RVTY) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers boosted its position in Revvity, Inc. (NYSE:RVTY - Free Report) by 9.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 223,067 shares of the company's stock after purchasing an additional 19,543 shares during the quarter. Rhumbline Advisers owned about 0.19% of Revvity worth $23,600,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Nissay Asset Management Corp Japan ADV grew its position in shares of Revvity by 0.6% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 15,023 shares of the company's stock valued at $1,682,000 after purchasing an additional 91 shares during the period. Quarry LP boosted its stake in Revvity by 45.7% in the 4th quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after buying an additional 95 shares during the last quarter. Signaturefd LLC grew its holdings in Revvity by 6.8% in the 4th quarter. Signaturefd LLC now owns 1,668 shares of the company's stock valued at $186,000 after buying an additional 106 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Revvity by 33.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company's stock valued at $58,000 after acquiring an additional 131 shares during the last quarter. Finally, Continuum Advisory LLC increased its stake in shares of Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company's stock valued at $53,000 after acquiring an additional 133 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Stock Up 1.0%

Shares of NYSE RVTY traded up $0.94 on Monday, hitting $92.91. The company had a trading volume of 1,157,602 shares, compared to its average volume of 957,626. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. Revvity, Inc. has a 12-month low of $87.70 and a 12-month high of $129.50. The firm has a market capitalization of $10.95 billion, a P/E ratio of 42.04, a PEG ratio of 3.82 and a beta of 0.97. The business has a 50 day moving average of $93.51 and a two-hundred day moving average of $107.43.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.96 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The firm had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. During the same period in the previous year, the company posted $0.98 EPS. Revvity's revenue for the quarter was up 2.3% on a year-over-year basis. As a group, equities research analysts forecast that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date of this dividend is Friday, July 18th. Revvity's payout ratio is 11.91%.

Analyst Ratings Changes

RVTY has been the topic of several research analyst reports. Barclays decreased their target price on shares of Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Raymond James reiterated an "outperform" rating and issued a $120.00 price target (down previously from $145.00) on shares of Revvity in a report on Tuesday, April 29th. Wells Fargo & Company dropped their price objective on Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, JPMorgan Chase & Co. reduced their target price on Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $125.64.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.